首页> 外文期刊>Digestive Diseases and Sciences >Liberal policy in living donor liver transplantation for hepatocellular carcinoma: lessons learned.
【24h】

Liberal policy in living donor liver transplantation for hepatocellular carcinoma: lessons learned.

机译:活体供体肝移植治疗肝细胞癌的自由政策:经验教训。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: Living donor liver transplantation (LDLT) in cases of hepatocellular carcinoma (HCC) that do not fulfil accepted tumor criteria continues to be a matter of controversy. The aim of this study was to evaluate survival and prognostic factors associated with a liberal exclusionary policy. MATERIAL AND METHODS: This is an analysis of data collected prospectively on 57 HCC patients who underwent LDLT at our institution between April 1998 and January 2007. RESULTS: Overall 3-year survival was 62%; this increased to 71% when 45-day mortality was excluded from the analysis. Age proved to be a predictor of survival irrespective of the 45-day mortality. In contrast, the Model for End stage Liver Disease (MELD) score predicted survival only when 45-day mortality was included in the analysis, while alpha fetoprotein (AFP) level predicted survival only when it was excluded. Significant cut-off values were patient age of over 60 years, MELD score above 22, and AFP level greater than 400 ng/ml. A scoring system was developed. Survival rate at 3 years--including 45-day mortality--was 72% for score =2 and 41% for score >2 (P = 0.0146). When 45-day mortality was excluded, the survival rate at 3 years was 90% for score =2 and 32% for score >2 (P = 0.00002). CONCLUSIONS: Our results could further enhance current guidelines on age, MELD score, and AFP level for patients with HCC being evaluated to undergo LDLT.
机译:背景:在不符合公认的肿瘤标准的肝细胞癌(HCC)病例中,活体供体肝移植(LDLT)仍是一个有争议的问题。这项研究的目的是评估与宽松的排除政策相关的生存率和预后因素。材料与方法:这是对前瞻性收集的1998年4月至2007年1月间在我院接受LDLT治疗的57例HCC患者的数据的分析。结果:3年总生存率为62%。如果将45天的死亡率排除在分析范围之外,则这一比例上升至71%。不论45天的死亡率如何,年龄都是生存的预测指标。相反,只有在分析中包括45天死亡率时,末期肝病模型(MELD)分数才能预测存活,而只有将甲胎蛋白(AFP)水平排除才可以预测存活。重要的临界值是患者年龄超过60岁,MELD评分高于22,AFP水平高于400 ng / ml。开发了计分系统。 3年生存率-包括45天死亡率-得分= 2的生存率为72%,得分> 2的生存率为41%(P = 0.0146)。如果排除45天的死亡率,则3分的生存率对于得分= 2为90%,对于得分> 2为32%(P = 0.00002)。结论:我们的结果可以进一步增强当前评估年龄的肝癌患者接受LDLT的年龄,MELD评分和AFP水平的指南。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号